| [1] |
Younossi ZM, Koenig AB, Abdelatif D, Fazel Y, Henry L, Wymer M. Global epidemiology of nonalcoholic fatty liver disease—meta-analytic assessment of prevalence, incidence, and outcomes. Hepatology 2016; 64(1):73-84.
|
| [2] |
Rinella ME, Lazarus JV, Ratziu V, Francque SM, Sanyal AJ, Kanwal F, et al. ; NAFLD Nomenclature Consensus Group. A multisociety Delphi consensus statement on new fatty liver disease nomenclature. J Hepatol 2023; 79 (6):1542-56.
|
| [3] |
Ye Q, Zou B, Yeo YH, Li J, Huang DQ, Wu Y, et al. Global prevalence, incidence, and outcomes of non-obese or lean non-alcoholic fatty liver disease: a systematic review and meta-analysis. Lancet Gastroenterol Hepatol 2020; 5 (8):739-52.
|
| [4] |
Estes C, Anstee QM, Arias-Loste MT, Bantel H, Bellentani S, Caballeria J, et al. Modeling NAFLD disease burden in China, France, Germany, Italy, Japan, Spain, United Kingdom, and United States for the period 2016-2030. J Hepatol 2018; 69(4):896-904.
|
| [5] |
Farrell GC, Larter CZ. Nonalcoholic fatty liver disease: from steatosis to cirrhosis. Hepatology 2006; 43(2 Suppl 1):S99-112.
|
| [6] |
George J, Anstee Q, Ratziu V, Sanyal A. NAFLD: the evolving landscape. J Hepatol 2018; 68(2):227-9.
|
| [7] |
Rumgay H, Arnold M, Ferlay J, Lesi O, Cabasag CJ, Vignat J, et al. Global burden of primary liver cancer in 2020 and predictions to 2040. J Hepatol 2022; 77 (6):1598-606.
|
| [8] |
Gadiparthi C, Spatz M, Greenberg S, Iqbal U, Kanna S, Satapathy SK, et al. NAFLD epidemiology, emerging pharmacotherapy, liver transplantation implications and the trends in the United States. J Clin Transl Hepatol 2020; 8(2):215-21.
|
| [9] |
Huang DQ, El-Serag HB, Loomba R. Global epidemiology of NAFLD-related HCC: trends, predictions, risk factors and prevention. Nat Rev Gastroenterol Hepatol 2021; 18(4):223-38.
|
| [10] |
Targher G, Byrne CD, Lonardo A, Zoppini G, Barbui C. Non-alcoholic fatty liver disease and risk of incident cardiovascular disease: a meta-analysis. J Hepatol 2016; 65(3):589-600.
|
| [11] |
Golabi P, Otgonsuren M, de Avila L, Sayiner M, Rafiq N, Younossi ZM. Components of metabolic syndrome increase the risk of mortality in nonalcoholic fatty liver disease (NAFLD). Medicine 2018; 97(13):e0214.
|
| [12] |
Mantovani A, Gatti D, Zoppini G, Lippi G, Bonora E, Byrne CD, et al. Association between nonalcoholic fatty liver disease and reduced bone mineral density in children: a meta-analysis. Hepatology 2019; 70(3):812-23.
|
| [13] |
Nasr P, Fredrikson M, Ekstedt M, Kechagias S. The amount of liver fat predicts mortality and development of type 2 diabetes in non-alcoholic fatty liver disease. Liver Int 2020; 40(5):1069-78.
|
| [14] |
Jang HR, Kang D, Sinn DH, Gu S, Cho SJ, Lee JE, et al. Nonalcoholic fatty liver disease accelerates kidney function decline in patients with chronic kidney disease: a cohort study. Sci Rep 2018; 8(1):4718.
|
| [15] |
McNeice K, Sandberg K. Updates in non-alcoholic fatty liver disease (NAFLD). Curr Probl Pediatr Adolesc Health Care 2020; 50(8):100844.
|
| [16] |
Hydes TJ, Ravi S, Loomba R, E Gray M. Evidence-based clinical advice for nutrition and dietary weight loss strategies for the management of NAFLD and NASH. Clin Mol Hepatol 2020; 26(4):383-400.
|
| [17] |
Yoshimoto S, Loo TM, Atarashi K, Kanda H, Sato S, Oyadomari S, et al. Obesityinduced gut microbial metabolite promotes liver cancer through senescence secretome. Nature 2013; 499(7456):97-101.
|
| [18] |
Dapito DH, Mencin A, Gwak GY, Pradere JP, Jang MK, Mederacke I, et al. Promotion of hepatocellular carcinoma by the intestinal microbiota and TLR4. Cancer Cell 2012; 21(4):504-16.
|
| [19] |
Caussy C, Hsu C, Lo MT, Liu A, Bettencourt R, Ajmera VH, et al. ; Genetics of NAFLD in Twins Consortium. Link between gut-microbiome derived metabolite and shared gene-effects with hepatic steatosis and fibrosis in NAFLD. Hepatology 2018; 68(3):918-32.
|
| [20] |
Kim DH, Jeong D, Kang IB, Kim H, Song KY, Seo KH. Dual function of Lactobacillus kefiri DH5 in preventing high-fat-diet-induced obesity: direct reduction of cholesterol and upregulation of PPAR-a in adipose tissue. Mol Nutr Food Res 2017; 61(11):1700252.
|
| [21] |
Chen Y, Liu Y, Zhou R, Chen X, Wang C, Tan X, et al. Associations of gut-floradependent metabolite trimethylamine-N-oxide, betaine and choline with non-alcoholic fatty liver disease in adults. Sci Rep 2016; 6(1):19076.
|
| [22] |
Behary J, Amorim N, Jiang XT, Raposo A, Gong L, McGovern E, et al. Gut microbiota impact on the peripheral immune response in non-alcoholic fatty liver disease related hepatocellular carcinoma. Nat Commun 2021; 12(1):187.
|
| [23] |
Rinninella E, Raoul P, Cintoni M, Franceschi F, Miggiano GAD, Gasbarrini A, et al. What is the healthy gut microbiota composition? A changing ecosystem across age, environment, diet, and diseases. Microorganisms 2019; 7(1):14.
|
| [24] |
Gu Y, Zhou G, Qin X, Huang S, Wang B, Cao H. The potential role of gut mycobiome in irritable bowel syndrome. Front Microbiol 2019; 10:1894.
|
| [25] |
Jiang L, Stärkel P, Fan JG, Fouts DE, Bacher P, Schnabl B. The gut mycobiome: a novel player in chronic liver diseases. J Gastroenterol 2021; 56(1):1-11.
|
| [26] |
Fotis D, Liu J, Dalamaga M. Could gut mycobiome play a role in NAFLD pathogenesis? Insights and therapeutic perspectives. Metabol Open 2022; 14:100178.
|
| [27] |
Mukherjee PK, Sendid B, Hoarau G, Colombel JF, Poulain D, Ghannoum MA. Mycobiota in gastrointestinal diseases. Nat Rev Gastroenterol Hepatol 2015; 12 (2):77-87.
|
| [28] |
Ahn J, Hayes RB. Environmental influences on the human microbiome and implications for noncommunicable disease. Annu Rev Public Health 2021; 42 (1):277-92.
|
| [29] |
Hou K, Wu ZX, Chen XY, Wang JQ, Zhang D, Xiao C, et al. Microbiota in health and diseases. Signal Transduct Target Ther 2022; 7(1):135.
|
| [30] |
Xia Y, Ren M, Yang J, Cai C, Cheng W, Zhou X, et al. Gut microbiome and microbial metabolites in NAFLD and after bariatric surgery: correlation and causality. Front Microbiol 2022; 13:1003755.
|
| [31] |
Schneider KM, Bieghs V, Heymann F, Hu W, Dreymueller D, Liao L, et al. CX3CR1 is a gatekeeper for intestinal barrier integrity in mice: limiting steatohepatitis by maintaining intestinal homeostasis. Hepatology 2015; 62(5):1405-16.
|
| [32] |
Bashiardes S, Shapiro H, Rozin S, Shibolet O, Elinav E. Non-alcoholic fatty liver and the gut microbiota. Mol Metab 2016; 5(9):782-94.
|
| [33] |
Shao L, Shi J, Fan X. Tiny but mighty: possible roles of bacterial extracellular vesicles in gut-liver crosstalk for non-alcoholic fatty liver disease. Clinical and Translational Dis 2022; 2(3):e115.
|
| [34] |
Schneider KM, Mohs A, Gui W, Galvez EJC, Candels LS, Hoenicke L, et al. Imbalanced gut microbiota fuels hepatocellular carcinoma development by shaping the hepatic inflammatory microenvironment. Nat Commun 2022; 13 (1):3964.
|
| [35] |
Kim S, Lee Y, Kim Y, Seo Y, Lee H, Ha J, et al. Akkermansia muciniphila prevents fatty liver disease, decreases serum triglycerides, and maintains gut homeostasis. Appl Environ Microbiol 2020; 86(7):e03004-19.
|
| [36] |
Maestri M, Santopaolo F, Pompili M, Gasbarrini A, Ponziani FR. Gut microbiota modulation in patients with non-alcoholic fatty liver disease: effects of current treatments and future strategies. Front Nutr 2023; 10:1110536.
|
| [37] |
Pierantonelli I, Svegliati-Baroni G. Nonalcoholic fatty liver disease: basic pathogenetic mechanisms in the progression from NAFLD to NASH. Transplantation 2019; 103(1):e1-13.
|
| [38] |
Parthasarathy G, Revelo X, Malhi H. Pathogenesis of nonalcoholic steatohepatitis: an overview. Hepatol Commun 2020; 4(4):478-92.
|
| [39] |
Kessoku T, Kobayashi T, Imajo K, Tanaka K, Yamamoto A, Takahashi K, et al. Endotoxins and non-alcoholic fatty liver disease. Front Endocrinol 2021; 12:770986.
|
| [40] |
Chen D, Le TH, Shahidipour H, Read SA, Ahlenstiel G. The role of gut-derived microbial antigens on liver fibrosis initiation and progression. Cells 2019; 8 (11):1324.
|
| [41] |
Huang XL, Zhang X, Fei XY, Chen ZG, Hao YP, Zhang S, et al. Faecalibacterium prausnitzii supernatant ameliorates dextran sulfate sodium induced colitis by regulating Th 17 cell differentiation. World J Gastroenterol 2016; 22(22):5201-10.
|
| [42] |
Soares JB, Pimentel-Nunes P, Roncon-Albuquerque R Jr, Leite-Moreira A. The role of lipopolysaccharide/toll-like receptor 4 signaling in chronic liver diseases. Hepatol Int 2010; 4(4):659-72.
|
| [43] |
Du J, Zhang J, Chen X, Zhang S, Zhang C, Liu H, et al. Neutrophil extracellular traps induced by pro-inflammatory cytokines enhance procoagulant activity in NASH patients. Clin Res Hepatol Gastroenterol 2022; 46(1):101697.
|
| [44] |
Chattopadhyay I, Gundamaraju R, Jha NK, Gupta PK, Dey A, Mandal CC, et al. Interplay between dysbiosis of gut microbiome, lipid metabolism, and tumorigenesis: can gut dysbiosis stand as a prognostic marker in cancer? Dis Markers 2022; 2022:2941248.
|
| [45] |
Xie G, Wang X, Huang F, Zhao A, Chen W, Yan J, et al. Dysregulated hepatic bile acids collaboratively promote liver carcinogenesis. Int J Cancer 2016; 139 (8):1764-75.
|
| [46] |
Yang S, Dai H, Lu Y, Li R, Gao C, Pan S. Trimethylamine N-oxide promotes cell proliferation and angiogenesis in colorectal cancer. J Immunol Res 2022; 2022:7043856.
|
| [47] |
Nicholson JK, Holmes E, Kinross J, Burcelin R, Gibson G, Jia W, et al. Host-gut microbiota metabolic interactions. Science 2012; 336(6086):1262-7.
|
| [48] |
Wu Y, Rong X, Pan M, Wang T, Yang H, Chen X, et al. Integrated analysis reveals the gut microbial metabolite TMAO promotes inflammatory hepatocellular carcinoma by upregulating POSTN. Front Cell Dev Biol 2022; 10:840171.
|
| [49] |
Yang AM, Inamine T, Hochrath K, Chen P, Wang L, Llorente C, et al. Intestinal fungi contribute to development of alcoholic liver disease. J Clin Invest 2017; 127(7):2829-41.
|
| [50] |
Chu H, Duan Y, Lang S, Jiang L, Wang Y, Llorente C, et al. The Candida albicans exotoxin candidalysin promotes alcohol-associated liver disease. J Hepatol 2020; 72(3):391-400.
|
| [51] |
Zeng S, Rosati E, Saggau C, Messner B, Chu H, Duan Y, et al. Candida albicansspecific Th 17 cell-mediated response contributes to alcohol-associated liver disease. Cell Host Microbe 2023; 31(3):389-404.e7.
|
| [52] |
Zhang LY, Zhan DL, Chen YY, Wang WH, He CY, Lin Y, et al. Aflatoxin B1 enhances pyroptosis of hepatocytes and activation of Kupffer cells to promote liver inflammatory injury via dephosphorylation of cyclooxygenase-2: an in vitro, ex vivo and in vivo study. Arch Toxicol 2019; 93(11):3305-20
|
| [53] |
Yang AM, Lin CY, Liu SH, Syu GD, Sun HJ, Lee KC, et al. Saccharomyces boulardii ameliorates non-alcoholic steatohepatitis in mice induced by a methioninecholine- deficient diet through gut-liver axis. Front Microbiol 2022; 13:887728.
|
| [54] |
Yu L, Zhao XK, Cheng ML, Yang GZ, Wang B, Liu HJ, et al. Saccharomyces boulardii administration changes gut microbiota and attenuates Dgalactosamine- induced liver injury. Sci Rep 2017; 7(1):1359.
|
| [55] |
Tarantino G, Citro V, Cataldi M. Findings from studies are congruent with obesity having a viral origin, but what about obesity-related NAFLD? Viruses 2021; 13(7):1285.
|
| [56] |
Park A, Zhao G. Mining the virome for insights into type 1 diabetes. DNA Cell Biol 2018; 37(5):422-5.
|
| [57] |
YangK, NiuJ, ZuoT, SunY, XuZ, TangW, etal. Alterations inthegutviromeinobesity and type 2 diabetesmellitus. Gastroenterology 2021; 161(4):1257-69.e13.
|
| [58] |
Norman JM, Handley SA, Baldridge MT, Droit L, Liu CY, Keller BC, et al. Disease-specific alterations in the enteric virome in inflammatory bowel disease. Cell 2015; 160(3):447-60.
|
| [59] |
Vrieze A, Van Nood E, Holleman F, Salojärvi J, Kootte RS, Bartelsman JFWM, et al. Transfer of intestinal microbiota from lean donors increases insulin sensitivity in individuals with metabolic syndrome. Gastroenterology 2012; 143(4):913-6.e7.
|
| [60] |
De Groot P, Scheithauer T, Bakker GJ, Prodan A, Levin E, Khan MT, et al. Donor metabolic characteristics drive effects of faecal microbiota transplantation on recipient insulin sensitivity, energy expenditure and intestinal transit time. Gut 2020; 69(3):502-12.
|
| [61] |
Witjes JJ, Smits LP, Pekmez CT, Prodan A, Meijnikman AS, Troelstra MA, et al. Donor fecal microbiota transplantation alters gut microbiota and metabolites in obese individuals with steatohepatitis. Hepatol Commun 2020; 4 (11):1578-90.
|
| [62] |
Craven L, Rahman A, Nair Parvathy S, Beaton M, Silverman J, Qumosani K, et al. Allogenic fecal microbiota transplantation in patients with nonalcoholic fatty liver disease improves abnormal small intestinal permeability: a randomized control trial. Am J Gastroenterol 2020; 115(7):1055-65.
|
| [63] |
Decraecker M, Dutartre D, Hiriart JB, Irles-Depé M, Marraud des Grottes H, Chermak F, et al. Long-term prognosis of patients with alcohol-related liver disease or non-alcoholic fatty liver disease according to metabolic syndrome or alcohol use. Liver Int 2022; 42(2):350-62.
|
| [64] |
Citi S. Intestinal barriers protect against disease. Science 2018; 359(6380):1097-8.
|
| [65] |
Miele L, Valenza V, La Torre G, Montalto M, Cammarota G, Ricci R, et al. Increased intestinal permeability and tight junction alterations in nonalcoholic fatty liver disease. Hepatology 2009; 49(6):1877-87.
|
| [66] |
Schneider KM, Kummen M, Trivedi PJ, Hov JR. Role of microbiome in autoimmune liver diseases. Hepatology 2023; 10:1091.
|
| [67] |
Bajaj JS, Heuman DM, Hylemon PB, Sanyal AJ, White MB, Monteith P, et al. Altered profile of human gut microbiome is associated with cirrhosis and its complications. J Hepatol 2014; 60(5):940-7.
|
| [68] |
Lang S, Schnabl B. Microbiota and fatty liver disease-the known, the unknown, and the future. Cell Host Microbe 2020; 28(2):233-44.
|
| [69] |
Wilson BC, Vatanen T, Jayasinghe TN, Leong KSW, Derraik JGB, Albert BB, et al. Strain engraftment competition and functional augmentation in a multi-donor fecal microbiota transplantation trial for obesity. Microbiome 2021; 9(1):107.
|
| [70] |
Morelli L, Capurso L. FAO/WHO guidelines on probiotics: 10 years later. J Clin Gastroenterol 2012; 46(Suppl):S1-2.
|
| [71] |
Hutkins RW, Krumbeck JA, Bindels LB, Cani PD, Fahey G Jr, Goh YJ, et al. Prebiotics: why definitions matter. Curr Opin Biotechnol 2016; 37:1-7.
|
| [72] |
Markowiak P, Śliżewska K. Effects of probiotics, prebiotics, and synbiotics on human health. Nutrients 2017; 9(9):1021.
|
| [73] |
Chong CYL, Orr D, Plank LD, Vatanen T, O’Sullivan JM, Murphy R. Randomised double-blind placebo-controlled trial of inulin with metronidazole in nonalcoholic fatty liver disease (NAFLD). Nutrients 2020; 12(4):937.
|
| [74] |
Aller R, De Luis DA, Izaola O, Conde R, Gonzalez Sagrado M, Primo D, et al. Effect of a probiotic on liver aminotransferases in nonalcoholic fatty liver disease patients: a double blind randomized clinical trial. Eur Rev Med Pharmacol Sci 2011; 15(9):1090-5.
|
| [75] |
Jiang W, Wu N, Wang X, Chi Y, Zhang Y, Qiu X, et al. Dysbiosis gut microbiota associated with inflammation and impaired mucosal immune function in intestine of humans with non-alcoholic fatty liver disease. Sci Rep 2015; 5(1):8096.
|
| [76] |
Raman M, Ahmed I, Gillevet PM, Probert CS, Ratcliffe NM, Smith S, et al. Fecal microbiome and volatile organic compound metabolome in obese humans with nonalcoholic fatty liver disease. Clin Gastroenterol Hepatol 2013; 11 (7):868-75.
|
| [77] |
Shen F, Zheng RD, Sun XQ, Ding WJ, Wang XY, Fan JG. Gut microbiota dysbiosis in patients with non-alcoholic fatty liver disease. Hepatobiliary Pancreat Dis Int 2017; 16(4):375-81.
|
| [78] |
Bakhshimoghaddam F, Shateri K, Sina M, Hashemian M, Alizadeh M.Daily consumption of synbiotic yogurt decreases liver steatosis in patients with nonalcoholic fatty liver disease: a randomized controlled clinical trial. J Nutr 2018; 148(8):1276-84.
|
| [79] |
Martins FS, Vieira AT, Elian SDA, Arantes RME, Tiago FCP, Sousa LP, et al. Inhibition of tissue inflammation and bacterial translocation as one of the protective mechanisms of Saccharomyces boulardii against Salmonella infection in mice. Microbes Infect 2013; 15(4):270-9.
|
| [80] |
Malaguarnera M, Vacante M, Antic T, Giordano M, Chisari G, Acquaviva R, et al. Bifidobacterium longum with fructo-oligosaccharides in patients with non alcoholic steatohepatitis. Dig Dis Sci 2012; 57(2):545-53.
|
| [81] |
Eslamparast T, Poustchi H, Zamani F, Sharafkhah M, Malekzadeh R, Hekmatdoost A. Synbiotic supplementation in nonalcoholic fatty liver disease: a randomized, double-blind, placebo-controlled pilot study. Am J Clin Nutr 2014; 99(3):535-42.
|
| [82] |
Neyrinck AM, Possemiers S, Verstraete W, De Backer F, Cani PD, Delzenne NM. Dietary modulation of clostridial cluster XIVa gut bacteria (Roseburia spp.) by chitin-glucan fiber improves host metabolic alterations induced by high-fat diet in mice. J Nutr Biochem 2012; 23(1):51-9.
|
| [83] |
Scorletti E, Afolabi PR, Miles EA, Smith DE, Almehmadi A, Alshathry A, et al. Synbiotics alter fecal microbiomes, but not liver fat or fibrosis, in a randomized trial of patients with nonalcoholic fatty liver disease. Gastroenterology 2020; 158(6):1597-610.
|
| [84] |
Khan MY, Mihali AB, Rawala MS, Aslam A, Siddiqui WJ. The promising role of probiotic and synbiotic therapy in aminotransferase levels and inflammatory markers in patients with nonalcoholic fatty liver disease—a systematic review and meta-analysis. Eur J Gastroenterol Hepatol 2019; 31(6):703-15.
|
| [85] |
Liu L, Li P, Liu Y, Zhang Y. Efficacy of probiotics and synbiotics in patients with nonalcoholic fatty liver disease: a meta-analysis. Dig Dis Sci 2019; 64 (12):3402-12.
|
| [86] |
Suk KT, Kim DJ. Gut microbiota: novel therapeutic target for nonalcoholic fatty liver disease. Expert Rev Gastroenterol Hepatol 2019; 13(3):193-204.
|
| [87] |
Tang Y, Huang J, Zhang WY, Qin S, Yang YX, Ren H, et al. Effects of probiotics on nonalcoholic fatty liver disease: a systematic review and meta-analysis. Therap Adv Gastroenterol 2019; 12:1756284819878046.
|
| [88] |
Cho MS, Kim SY, Suk KT, Kim BY. Modulation of gut microbiome in nonalcoholic fatty liver disease: pro-, pre-, syn-, and antibiotics. J Microbiol 2018; 56(12):855-67.
|
| [89] |
Khalesi S, Johnson DW, Campbell K, Williams S, Fenning A, Saluja S, et al. Effect of probiotics and synbiotics consumption on serum concentrations of liver function test enzymes: a systematic review and meta-analysis. Eur J Nutr 2018; 57(6):2037-53.
|
| [90] |
Barengolts E. Gut microbiota, prebiotics, probiotics, and synbiotics in management of obesity and prediabetes: review of randomized controlled trials. Endocr Pract 2016; 22(10):1224-34.
|
| [91] |
Sharpton SR, Maraj B, Harding-Theobald E, Vittinghoff E, Terrault NA. Gut microbiome-targeted therapies in nonalcoholic fatty liver disease: a systematic review, meta-analysis, and meta-regression. Am J Clin Nutr 2019; 110(1):139-49.
|
| [92] |
Chiang JYL. Bile acid metabolism and signaling. Compr Physiol 2013; 3 (3):1191-212.
|
| [93] |
Tan X, Liu Y, Long J, Chen S, Liao G, Wu S, et al. Trimethylamine N-oxide aggravates liver steatosis through modulation of bile acid metabolism and inhibition of farnesoid X receptor signaling in nonalcoholic fatty liver disease. Mol Nutr Food Res 2019; 63(17):e1900257.
|
| [94] |
Schneider KM, Albers S, Trautwein C. Role of bile acids in the gut-liver axis. J Hepatol 2018; 68(5):1083-5.
|
| [95] |
Negroni A, Fiaschini N, Palone F, Vitali R, Colantoni E, Laudadio I, et al. Intestinal inflammation alters the expression of hepatic bile acid receptors causing liver impairment. J Pediatr Gastroenterol Nutr 2020; 71(2):189-96.
|
| [96] |
Zhao L, Xuan Z, Song W, Zhang S, Li Z, Song G, et al. A novel role for farnesoid X receptor in the bile acid-mediated intestinal glucose homeostasis. J Cell Mol Med 2020; 24(21):12848-61.
|
| [97] |
Molinaro A, Wahlström A, Marschall HU. Role of bile acids in metabolic control. Trends Endocrinol Metab 2018; 29(1):31-41.
|
| [98] |
Puri P, Daita K, Joyce A, Mirshahi F, Santhekadur PK, Cazanave S, et al. The presence and severity of nonalcoholic steatohepatitis is associated with specific changes in circulating bile acids. Hepatology 2018; 67(2):534-48.
|
| [99] |
Albillos A, de Gottardi A, Rescigno M. The gut-liver axis in liver disease: pathophysiological basis for therapy. J Hepatol 2020; 72(3):558-77.
|
| [100] |
Fan YY, Ding W, Zhang C, Fu L, Xu DX, Chen X. Obeticholic acid prevents carbon tetrachloride-induced liver fibrosis through interaction between farnesoid X receptor and Smad3. Int Immunopharmacol 2019; 77:105911.
|
| [101] |
Goto T, Itoh M, Suganami T, Kanai S, Shirakawa I, Sakai T, et al. Obeticholic acid protects against hepatocyte death and liver fibrosis in a murine model of nonalcoholic steatohepatitis. Sci Rep 2018; 8(1):8157.
|
| [102] |
Arab JP, Martin-Mateos RM, Shah VH. Gut-liver axis, cirrhosis and portal hypertension: the chicken and the egg. Hepatol Int 2018; 12(Suppl 1):24-33.
|
| [103] |
Sayin SI, Wahlström A, Felin J, Jäntti S, Marschall HU, Bamberg K, et al. Gut microbiota regulates bile acid metabolism by reducing the levels of taurobeta- muricholic acid, a naturally occurring FXR antagonist. Cell Metab 2013; 17(2):225-35.
|
| [104] |
Said I, Ahad H, Said A. Gut microbiome in non-alcoholic fatty liver disease associated hepatocellular carcinoma: current knowledge and potential for therapeutics. World J Gastrointest Oncol 2022; 14(5):947-58.
|
| [105] |
Ma C, Han M, Heinrich B, Fu Q, Zhang Q, Sandhu M, et al. Gut microbiomemediated bile acid metabolism regulates liver cancer via NKT cells. Science 2018; 360(6391):eaan5931.
|
| [106] |
Mullard A. FDA rejects NASH drug. Nat Rev Drug Discov 2020; 19(8):501.
|
| [107] |
Mascolini M.Aldafermin meets 48-week primary and secondary endpoints for MASH cirrhosis. In: Proceedings of the AASLD The Liver Meeting; 2023 Nov 10; Boston, USA.
|
| [108] |
Rau M, Rehman A, Dittrich M, Groen AK, Hermanns HM, Seyfried F, c Fecal SCFAs and SCFA-producing bacteria in gut microbiome of human NAFLD as a putative link to systemic T-cell activation and advanced disease. United European Gastroenterol J 2018; 6(10):1496-507.
|
| [109] |
Lu Y, Fan C, Li P, Lu Y, Chang X, Qi K. Short chain fatty acids prevent high-fatdiet- induced obesity in mice by regulating G protein-coupled receptors and gut microbiota. Sci Rep 2016; 6(1):37589.
|
| [110] |
Schauber J, Svanholm C, Termén S, Iffland K, Menzel T, Scheppach W,W Expression of the cathelicidin LL-37 is modulated by short chain fatty acids in colonocytes: relevance of signalling pathways. Gut 2003; 52(5):735-41.
|
| [111] |
Zhang S, Zhao J, Xie F, He H, Johnston LJ, Dai X, et al. Dietary fiber-derived short-chain fatty acids: a potential therapeutic target to alleviate obesityrelated nonalcoholic fatty liver disease. Obes Rev 2021; 22(11):e13316.
|
| [112] |
Smirnova E, Puri P, Muthiah MD, Daitya K, Brown R, Chalasani N, et al. Fecal microbiome distinguishes alcohol consumption from alcoholic hepatitis but does not discriminate disease severity. Hepatology 2020; 72(1):271-86.
|
| [113] |
Pérez-Reytor D, Puebla C, Karahanian E, García K. Use of short-chain fatty acids for the recovery of the intestinal epithelial barrier affected by bacterial toxins. Front Physiol 2021;12:650313.
|
| [114] |
Gao Y, Davis B, Zhu W, Zheng N, Meng D, Walker WA. Short-chain fatty acid butyrate, a breast milk metabolite, enhances immature intestinal barrier function genes in response to inflammation in vitro and in vivo. Am J Physiol Gastrointest Liver Physiol 2021; 320(4):G521-30.
|
| [115] |
Schwenger KJ, Clermont-Dejean N, Allard JP. The role of the gut microbiome in chronic liver disease: the clinical evidence revised. JHEP Rep 2019; 1(3):214-26.
|
| [116] |
Morrison DJ, Preston T. Formation of short chain fatty acids by the gut microbiota and their impact on human metabolism. Gut Microbes 2016; 7 (3):189-200.
|
| [117] |
Tabat MW, Marques TM, Markgren M, Löfvendahl L, Brummer RJ, Wall R. Acute effects of butyrate on induced hyperpermeability and tight junction protein expression in human colonic tissues. Biomolecules 2020; 10(5):766.
|
| [118] |
Mariadason JM, Barkla DH, Gibson PR.E ffect of short-chain fatty acids on paracellular permeability in Caco-2 intestinal epithelium model. Am J Physiol 1997; 272(4 Pt 1):G705-12.
|
| [119] |
Peng L, Li ZR, Green RS, Holzman IR, Lin J. Butyrate enhances the intestinal barrier by facilitating tight junction assembly via activation of AMP-activated protein kinase in Caco-2 cell monolayers. J Nutr 2009; 139(9):1619-25.
|
| [120] |
Zhao ZH, Xin FZ, Xue Y, Hu Z, Han Y, Ma F, et al. Indole-3-propionic acid inhibits gut dysbiosis and endotoxin leakage to attenuate steatohepatitis in rats. Exp Mol Med 2019; 51(9):1-14.
|
| [121] |
Jakobsdottir G, Xu J, Molin G, Ahrné S, Nyman M. High-fat diet reduces the formation of butyrate, but increases succinate, inflammation, liver fat and cholesterol in rats, while dietary fibre counteracts these effects. PLoS ONE 2013; 8(11):e80476.
|
| [122] |
Den Besten G, Bleeker A, Gerding A, van Eunen K, Havinga R, van Dijk TH, et al. Short-chain fatty acids protect against high-fat diet-induced obesity via a PPARc-dependent switch from lipogenesis to fat oxidation. Diabetes 2015; 64(7):2398-408.
|
| [123] |
Zhou D, Chen YW, Zhao ZH, Yang RX, Xin FZ, Liu XL, et al. Sodium butyrate reduces high-fat diet-induced non-alcoholic steatohepatitis through upregulation of hepatic GLP-1R expression. Exp Mol Med 2018; 50(12):1-12.
|
| [124] |
Tayyeb JZ, Popeijus HE, Mensink RP, Konings MCJM, Mokhtar FBA, Plat J. Short-chain fatty acids (except hexanoic acid) lower NF-jB transactivation, which rescues inflammation-induced decreased apolipoprotein A-I transcription in HepG2 cells. Int J Mol Sci 2020; 21(14):5088.
|
| [125] |
Pirozzi C, Lama A, Annunziata C, Cavaliere G, De Caro C, Citraro R, et al. Butyrate prevents valproate-induced liver injury: in vitro and in vivo evidence. FASEB J 2020; 34(1):676-90.
|
| [126] |
Hu J, Luo H, Jiang Y, Chen P. Dietary capsaicin and antibiotics act synergistically to reduce non-alcoholic fatty liver disease induced by high fat diet in mice. Oncotarget 2017; 8(24):38161-75.
|
| [127] |
Bajaj JS, Khoruts A. Microbiota changes and intestinal microbiota transplantation in liver diseases and cirrhosis. J Hepatol 2020; 72(5):1003-27.
|
| [128] |
Jian J, Nie MT, Xiang B, Qian H, Yin C, Zhang X, et al. Rifaximin ameliorates non-alcoholic steatohepatitis in mice through regulating gut microbiomerelated bile acids. Front Pharmacol 2022; 13:841132.
|
| [129] |
Enomoto M, Kaji K, Nishimura N, Fujimoto Y, Murata K, Takeda S, et al. Rifaximin and lubiprostone mitigate liver fibrosis development by repairing gut barrier function in diet-induced rat steatohepatitis. Dig Liver Dis 2022; 54 (10):1392-402.
|
| [130] |
Israelsen M, Madsen BS, Torp N, Johansen S, Hansen CD, Detlefsen S, et al. Rifaximin-a for liver fibrosis in patients with alcohol-related liver disease (GALA-RIF): a randomised, double-blind, placebo-controlled, phase 2 trial. Lancet. Gastroenterol Hepatol 2023; 8(6):523-32.
|
| [131] |
Abdel-Razik A, Mousa N, Shabana W, Refaey M, Elzehery R, Elhelaly R, et al. Rifaximin in nonalcoholic fatty liver disease: hit multiple targets with a single shot. Eur J Gastroenterol Hepatol 2018; 30(10):1237-46.
|
| [132] |
Cobbold JFL, Atkinson S, Marchesi JR, Smith A, Wai SN, Stove J, et al. Rifaximin in non-alcoholic steatohepatitis: an open-label pilot study. Hepatol Res 2018; 48(1):69-77.
|
| [133] |
Toubal A, Kiaf B, Beaudoin L, Cagninacci L, Rhimi M, Fruchet B, et al. Mucosalassociated invariant T cells promote inflammation and intestinal dysbiosis leading to metabolic dysfunction during obesity. Nat Commun 2020; 11 (1):3755.
|
| [134] |
Komiyama S, Yamada T, Takemura N, Kokudo N, Hase K, Kawamura YI. Profiling of tumour-associated microbiota in human hepatocellular carcinoma. Sci Rep 2021; 11(1):10589.
|
| [135] |
Loomba R, Seguritan V, Li W, Long T, Klitgord N, Bhatt A, et al. Gut microbiome-based metagenomic signature for non-invasive detection of advanced fibrosis in human nonalcoholic fatty liver disease. Cell Metab 2017; 25(5):1054-62.
|
| [136] |
Duan Y, Llorente C, Lang S, Brandl K, Chu H, Jiang L, et al. Bacteriophage targeting of gut bacterium attenuates alcoholic liver disease. Nature 2019; 575(7783):505-11.
|
| [137] |
Doestzada M, Vila AV, Zhernakova A, Koonen DPY, Weersma RK, Touw DJ, et al. Pharmacomicrobiomics: a novel route towards personalized medicine? Protein Cell 2018; 9(5):432-45.
|
| [138] |
Huang W, Zhang W. Pharmacogenomics in precision medicine: from a perspective of ethnic differences. Berlin: Springer; 2020. p. 181-99.
|
| [139] |
Spear BB, Heath-Chiozzi M, Huff J. Clinical application of pharmacogenetics. Trends Mol Med 2001; 7(5):201-4.
|
| [140] |
Forslund K, Hildebrand F, Nielsen T, Falony G, Le Chatelier E, Sunagawa S, et al. MetaHIT Consortium. Disentangling type 2 diabetes and metformin treatment signatures in the human gut microbiota. Nature 2015; 528(7581):262-6.
|
| [141] |
Bryrup T, Thomsen CW, Kern T, Allin KH, Brandslund I, Jørgensen NR, et al. Metformin-induced changes of the gut microbiota in healthy young men: results of a non-blinded, one-armed intervention study. Diabetologia 2019; 62(6):1024-35.
|
| [142] |
Lee H, Ko G. Effect of metformin on metabolic improvement and gut microbiota. Appl Environ Microbiol 2014; 80(19):5935-43.
|
| [143] |
Lee PC, Wu CJ, Hung YW, Lee CJ, Chao Y, Hou MC, et al. Association of gut microbiota and metabolites with tumor response to immune checkpoint inhibitors in patients with unresectable hepatocellular carcinoma. JCO 2021; 39(15 suppl):e16165.
|
| [144] |
Routy B, Le Chatelier E, Derosa L, Duong CPM, Alou MT, Daillère R, et al. Gut microbiome influences efficacy of PD-1-based immunotherapy against epithelial tumors. Science 2018; 359(6371):91-7.
|
| [145] |
Sivan A, Corrales L, Hubert N, Williams JB, Aquino-Michaels K, Earley ZM, et al. Commensal Bifidobacterium promotes antitumor immunity and facilitates anti-PD-L1 efficacy. Science 2015; 350(6264):1084-9.
|
| [146] |
Vétizou M, Pitt JM, Daillère R, Lepage P, Waldschmitt N, Flament C, et al. Anticancer immunotherapy by CTLA-4 blockade relies on the gut microbiota. Science 2015; 350(6264):1079-84.
|
| [147] |
Sydor S, Best J, Messerschmidt I, Manka P, Vilchez-Vargas R, Brodesser S, et al. Altered microbiota diversity and bile acid signaling in cirrhotic and noncirrhotic NASH-HCC. Clin Transl Gastroenterol 2020; 11(3):e00131.
|
| [148] |
Engelmann C, Sheikh M, Sharma S, Kondo T, Loeffler-Wirth H, Zheng YB, et al. Toll-like receptor 4 is a therapeutic target for prevention and treatment of liver failure. J Hepatol 2020; 73(1):102-12.
|
| [149] |
Yu LX, Schwabe RF. The gut microbiome and liver cancer: mechanisms and clinical translation. Nat Rev Gastroenterol Hepatol 2017; 14(9):527-39.
|
| [150] |
Sharma P, Siddiqui BA, Anandhan S, Yadav SS, Subudhi SK, Gao J, et al. The next decade of immune checkpoint therapy. Cancer Discov 2021; 11 (4):838-57.
|
| [151] |
Haslam A, Prasad V. Estimation of the percentage of US patients with cancer who are eligible for and respond to checkpoint inhibitor immunotherapy drugs. JAMA Netw Open 2019; 2(5):e192535.
|
| [152] |
Routy B, Lenehan JG, Miller Jr WH, Jamal R, Messaoudene M, Daisley BA, et al. Fecal microbiota transplantation plus anti-PD-1 immunotherapy in advanced melanoma: a phase I trial. Nat Med 2023; 29(8):2121-32.
|
| [153] |
Shaikh FY, White JR, Gills JJ, Hakozaki T, Richard C, Routy B, et al. A uniform computational approach improved on existing pipelines to reveal microbiome biomarkers of nonresponse to immune checkpoint inhibitors. Clin Cancer Res 2021; 27(9):2571-83.
|
| [154] |
Zheng Y, Wang T, Tu X, Huang Y, Zhang H, Tan D, et al. Gut microbiome affects the response to anti-PD-1 immunotherapy in patients with hepatocellular carcinoma. J Immunother Cancer 2019; 7(1):193.
|
PDF(1155 KB)
